NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Weill Medical College of Cornell University
Conditions: HIV Infections, Renal Transplant Rejection
Interventions: BIC/F/TAF 50Mg-200Mg-25Mg Tablet
Countries: United States
This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given. Participants will be followed for 48 weeks in order to monitor the efficacy, safety and tolerability of BIC/F/TAF. The investigator hypothesizes that BIC/F/TAF will be an important addition to the management of HIV-positive post renal transplant patients, especially since it is a one pill daily dosing regimen, thereby decreasing the pill burden in this population.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * At least 18 years old on day of signing informed consent * Positive for human immunodeficiency virus (HIV) * Received a previous renal transplant * Must have controlled HIV infection for at least 3 months prior to enrollment Exclusion Criteria: * Received a kidney from a donor who was HIV positive (unless a false positive) * Currently taking BIC/F/TAF for treatment of HIV * Has allergies to any of the HIV medications in BIC/F/TAF (bictegravir, emtricitabine, or tenofovir alafenamide) * Currently taking dofetilide or rifampin * Is pregnant or breastfeeding
- New York, New York, United States